Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis

BackgroundGetting access to authentic human drug metabolites is an important issue during the drug discovery and development process. Employing recombinant microorganisms as whole-cell biocatalysts constitutes an elegant alternative to organic synthesis to produce these compounds. The present work aimed for the generation of an efficient whole-cell catalyst based on the flavin monooxygenase isoform 2 (FMO2), which is part of the human phase I metabolism.ResultsWe show for the first time the functional expression of human FMO2 in E. coli. Truncations of the C-terminal membrane anchor region did not result in soluble FMO2 protein, but had a significant effect on levels of recombinant protein. The FMO2 biocatalysts were employed for substrate screening purposes, revealing trifluoperazine and propranolol as FMO2 substrates. Biomass cultivation on the 100 L scale afforded active catalyst for biotransformations on preparative scale. The whole-cell conversion of trifluoperazine resulted in perfectly selective oxidation to 48 mg (46% yield) of the corresponding N1-oxide with a purity >98%.ConclusionsThe generated FMO2 whole-cell catalysts are not only useful as screening tool for human metabolites of drug molecules but more importantly also for their chemo- and regioselective preparation on the multi-milligram scale.

[1]  E. Hodgson,et al.  Formation of hydrogen peroxide and N-hydroxylated amines catalyzed by pulmonary flavin-containing monooxygenases in the presence of primary alkylamines. , 1986, Archives of biochemistry and biophysics.

[2]  L. Goracci,et al.  Flavin monooxygenase metabolism: why medicinal chemists should matter. , 2014, Journal of medicinal chemistry.

[3]  D. Williams,et al.  Characterization of expressed full-length and truncated FMO2 from rhesus monkey. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[4]  David E. Williams,et al.  Human flavin-containing monooxygenase form 2 S-oxygenation: sulfenic acid formation from thioureas and oxidation of glutathione. , 2004, Chemical research in toxicology.

[5]  G. Gilardi,et al.  In vitro drug metabolism by C-terminally truncated human flavin-containing monooxygenase 3. , 2012, Biochemical pharmacology.

[6]  Anton Glieder,et al.  Expression of recombinant human flavin monooxygenase and moclobemide-N-oxide synthesis on multi-mg scale. , 2012, Chemical communications.

[7]  I. Phillips,et al.  The Flavin-containing Monooxygenase 2 Gene (FMO2) of Humans, but Not of Other Primates, Encodes a Truncated, Nonfunctional Protein* , 1998, The Journal of Biological Chemistry.

[8]  K. Midha,et al.  Synthesis of the N-oxides of phenothiazine antipsychotic agents. , 1993, Journal of pharmaceutical sciences.

[9]  D. Williams,et al.  Substrate specificity of the rabbit lung flavin-containing monooxygenase for amines: oxidation products of primary alkylamines. , 1986, Molecular pharmacology.

[10]  S Ohmori,et al.  Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[11]  S. Sommer,et al.  Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[12]  R Scott Obach,et al.  Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. , 2009, Chemical research in toxicology.

[13]  T Ishizaki,et al.  Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2. , 1995, British journal of clinical pharmacology.

[14]  M. Shimizu,et al.  Molecular and functional characterization of flavin-containing monooxygenases in cynomolgus macaque. , 2013, Biochemical pharmacology.

[15]  I. Phillips,et al.  Human Flavin-Containing Monooxygenase 2.1 Catalyzes Oxygenation of the Antitubercular Drugs Thiacetazone and Ethionamide , 2009, Drug Metabolism and Disposition.

[16]  David E. Williams,et al.  Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes. , 2008, Toxicology and applied pharmacology.

[17]  B. Witholt,et al.  Using proteins in their natural environment: potential and limitations of microbial whole-cell hydroxylations in applied biocatalysis. , 2001, Current opinion in biotechnology.

[18]  S. Nath,et al.  An Evaluation of the Efficacy of Aspirin and Benzydamine Hydrochloride Gargle for Attenuating Postoperative Sore Throat: A Prospective, Randomized, Single-Blind Study , 2006, Anesthesia and analgesia.

[19]  D. Williams,et al.  Rabbit lung flavin-containing monooxygenase is immunochemically and catalytically distinct from the liver enzyme. , 1984, Biochemical and biophysical research communications.

[20]  David E. Williams,et al.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. , 2005, Pharmacology & therapeutics.

[21]  L H Overby,et al.  Characterization of flavin-containing monooxygenase 5 (FMO5) cloned from human and guinea pig: evidence that the unique catalytic properties of FMO5 are not confined to the rabbit ortholog. , 1995, Archives of biochemistry and biophysics.

[22]  K. Veeramah,et al.  The potentially deleterious functional variant flavin-containing monooxygenase 2*1 is at high frequency throughout sub-Saharan Africa , 2008, Pharmacogenetics and genomics.

[23]  L. Terada,et al.  Porcine FAD-containing monooxygenase metabolizes lidocaine, bupivacaine and propranolol in vitro. , 2004, Life sciences.

[24]  David E. Williams,et al.  C-Terminal truncation of rabbit flavin-containing monooxygenase isoform 2 enhances solubility. , 2006, Archives of biochemistry and biophysics.

[25]  E. Hodgson,et al.  Molecular cloning, sequencing, and expression in Escherichia coli of mouse flavin-containing monooxygenase 3 (FMO3): comparison with the human isoform. , 1997, Archives of biochemistry and biophysics.

[26]  J. Cashman,et al.  Expression in Escherichia coli of the flavin-containing monooxygenase D (form II) from adult human liver: determination of a distinct tertiary amine substrate specificity. , 1993, Chemical research in toxicology.

[27]  C. Miranda,et al.  Isoform specificity of N-deacetyl ketoconazole by human and rabbit flavin-containing monooxygenases. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[28]  David E. Williams,et al.  DIFFERENCES IN FMO2*1 ALLELIC FREQUENCY BETWEEN HISPANICS OF PUERTO RICAN AND MEXICAN DESCENT , 2004, Drug Metabolism and Disposition.

[29]  D. Williams,et al.  Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in African-Americans. , 2000, Toxicology and applied pharmacology.

[30]  J. Soglia,et al.  Evaluation of the metabolism of propranolol by linear ion trap technology in mouse, rat, dog, monkey, and human cryopreserved hepatocytes. , 2009, Rapid communications in mass spectrometry : RCM.

[31]  R. Philpot,et al.  Functional characterization of flavin-containing monooxygenase 1B1 expressed in Saccharomyces cerevisiae and Escherichia coli and analysis of proposed FAD- and membrane-binding domains. , 1993, The Journal of biological chemistry.

[32]  David E. Williams,et al.  Flavin-containing monooxygenase S-oxygenation of a series of thioureas and thiones. , 2014, Toxicology and applied pharmacology.

[33]  H. Schwab,et al.  An efficient plasmid vector for expression cloning of large numbers of PCR fragments in Escherichia coli , 2007, Applied Microbiology and Biotechnology.